Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.63 +3.8%	$1.53	$1.05 ▼ $5.17	$170M	0.3	1.35 million shs	779,761 shs
CRSP CRISPR Therapeutics	$55.00 -1.7%	$51.60	$30.04 ▼ $71.13	$5.09B	1.8	3.64 million shs	1.60 million shs
OTLK Oncobiologics	$1.90 +3.3%	$1.90	$0.87 ▼ $8.32	$61.76M	0.26	914,678 shs	540,897 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+1.29%	+2.61%	+8.28%	+24.60%	+31.93%
CRSP CRISPR Therapeutics	-0.67%	-0.53%	+2.08%	+57.10%	+18.38%
OTLK Oncobiologics	-2.13%	-6.12%	-2.65%	+19.87%	-73.75%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.162 of 5 stars	3.6	1.0	2.5	1.7	0.6
CRSP CRISPR Therapeutics	3.6694 of 5 stars	4.3	2.0	3.7	3.3	0.6
OTLK Oncobiologics	2.4082 of 5 stars	3.4	4.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.11	Buy	$8.71	434.62% Upside
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	30.18% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	405.26% Upside

Current Analyst Ratings Breakdown

Latest ACRS, CRSP, and OTLK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/10/2025	ACRS Aclaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00

(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$18.72M	9.43	N/A	N/A	$1.44 per share	1.13
CRSP CRISPR Therapeutics	$37.31M	134.07	N/A	N/A	$18.81 per share	2.92
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$132.07M	-$1.39	N/A	N/A	N/A	-802.03%	-33.33%	-23.84%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	N/A
OTLK Oncobiologics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-271.12%	8/13/2025 (Estimated)

Latest ACRS, CRSP, and OTLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q3 2025	OTLK Oncobiologics	-$0.42	N/A	N/A	N/A	$1.66 million	N/A
8/7/2025	Q2 2025	ACRS Aclaris Therapeutics	-$0.14	-$0.13	+$0.01	-$0.13	$1.34 million	$1.78 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
5/15/2025	Q2 2025	OTLK Oncobiologics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	5.06	5.06
CRSP CRISPR Therapeutics	N/A	16.61	15.64
OTLK Oncobiologics	N/A	0.72	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
CRSP CRISPR Therapeutics	69.20%
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
CRSP CRISPR Therapeutics	4.30%
OTLK Oncobiologics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	101.35 million	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable

ACRS, CRSP, and OTLK Headlines

Recent News About These Companies

Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Consensus Target Price from Analysts

August 8 at 2:01 AM | americanbankingnews.com

Oncobiologics (OTLK) Projected to Post Quarterly Earnings on Wednesday

August 7 at 5:52 AM | marketbeat.com

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages

August 5 at 4:33 AM | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Trading Down 1.5% - Should You Sell?

August 3, 2025 | marketbeat.com

New Strong Buy Stocks for July 30th

July 30, 2025 | zacks.com

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

July 24, 2025 | globenewswire.com

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Analysts

July 11, 2025 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Trading Up 4.5% - Still a Buy?

July 8, 2025 | marketbeat.com

OTLK Outlook Therapeutics, Inc. - Seeking Alpha

July 2, 2025 | seekingalpha.com

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

July 1, 2025 | globenewswire.com

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

June 18, 2025 | globenewswire.com

Microsoft shares temp fix for Outlook crashes when opening emails

June 17, 2025 | bleepingcomputer.comB

CFA Institute 2025 Graduate Outlook Survey: Finance Top Career Choice

June 12, 2025 | tmcnet.com

Steve Wilks Pleased With Jets Defensive Outlook

June 12, 2025 | msn.com

Microsoft Outlook to block more risky attachments used in attacks

June 12, 2025 | bleepingcomputer.comB

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

June 11, 2025 | pharmaceutical-technology.comP

Outlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | finanznachrichten.de

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | globenewswire.com

Highlights | Outlook Planet’s C³ Summit & Awards 2025

June 7, 2025 | outlookbusiness.comO

Natural Gas Price Outlook – Natural Gas Continues to See Same Resistance Level

June 7, 2025 | fxempire.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRS, CRSP, and OTLK Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.63 +0.06 (+3.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.60 -0.03 (-2.09%)

As of 07:56 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

CRISPR Therapeutics NASDAQ:CRSP

$55.00 -0.96 (-1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$55.14 +0.15 (+0.26%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Oncobiologics NASDAQ:OTLK

$1.90 +0.06 (+3.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 +0.03 (+1.32%)

As of 07:50 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time